Estrace vs. Climara

See how Estrace and Climara compare on approved uses, dosing, side effects, and cost.

Key Takeaways

  • Estrace and Climara both deliver the hormone estradiol for menopausal hot flashes, vaginal atrophy, and bone loss, but Estrace is a daily pill while Climara is a once-weekly skin patch.

  • Estrace is also FDA-approved for palliative treatment of certain breast and prostate cancers, a use Climara does not have.

  • Because Climara bypasses the liver on its way into the bloodstream, it may carry a lower clot risk than oral Estrace, though both carry boxed warnings for cardiovascular disease, dementia, and cancer risk.

Estrace vs. Climara Drug Summary

Estrace

Estrace is an oral estradiol tablet, a type of estrogen hormone therapy, used to treat menopausal hot flashes, vaginal atrophy, and hormone deficiency, and to help prevent osteoporosis. It is also FDA-approved for palliative treatment of certain breast and prostate cancers. Estrace is taken as a daily tablet in strengths from 0.5 mg to 2 mg.

Climara

Climara is a transdermal estradiol patch, the same hormone used in Estrace, applied to treat menopausal hot flashes, vaginal atrophy, and hormone deficiency, and to help prevent osteoporosis. It comes in six patch strengths and is changed just once a week. Climara is not approved for cancer treatment but is sometimes used off-label for feminizing hormone therapy.

Estrace vs. Climara Side Effects

Estrace

Most common
Edema (rate not quantified in label)
Headache (rate not quantified in label)
Breast tenderness/enlargement (rate not quantified in label)
Abdominal cramping/bloating (rate not quantified in label)

Climara

Most common
Edema (≥10%)
Headache (≥10%)
Breast pain (≥10%)
Abdominal pain (≥10%)

Estrace vs. Climara Dosage

Estrace

Dosage
Dosage Table
STAGE DOSE WHEN
Starting dose 0.5 mg daily At the start
Maximum dose 10 mg three times daily If needed
Dose changes 4 increases As tolerated

Climara

Dosage
Dosage Table
STAGE DOSE WHEN
Starting dose 0.025 mg/day patch At the start
Maximum dose 0.1 mg/day patch If needed
Dose changes 5 increases As tolerated

Estrace vs. Climara Indications

Estrace

Estrace treats moderate to severe hot flashes and vaginal atrophy caused by menopause, as well as hormone deficiency from ovarian failure, hypogonadism, or surgery. It is also FDA-approved to help prevent postmenopausal osteoporosis and, at higher doses, to palliate certain hormone-sensitive breast and prostate cancers.

  • Moderate to severe hot flashes of menopause

  • Vulvar and vaginal atrophy

  • Hypoestrogenism from hypogonadism or ovarian failure

  • Prevention of postmenopausal osteoporosis

  • Palliative treatment of breast or prostate cancer

Climara

Climara treats the same core menopausal symptoms as Estrace, hot flashes and vaginal atrophy, along with hormone deficiency from hypogonadism or ovarian failure. It is also FDA-approved to help prevent postmenopausal osteoporosis and is sometimes used off-label as part of feminizing hormone therapy for transgender women.

  • Moderate to severe hot flashes of menopause

  • Vulvar and vaginal atrophy

  • Hypoestrogenism from hypogonadism or ovarian failure

  • Prevention of postmenopausal osteoporosis

  • Off-label: feminizing hormone therapy (transgender women)

Estrace vs. Climara Pros and Cons

Estrace

Estrace is an oral estradiol tablet with one of the longest track records of any estrogen product, available in several strengths for both menopausal symptoms and hormone-sensitive cancer palliation. Because it is swallowed, it passes through the liver first, which carries a higher relative clot risk than transdermal estrogen.

Pros

  • FDA-approved for palliative treatment of breast and prostate cancer

  • Multiple oral strengths allow dosing for severe symptoms

  • Long-established generic tablet with decades of clinical use

Cons

  • Oral route means first-pass liver metabolism and higher clot risk

  • Requires taking a pill every day rather than weekly

  • 2 mg tablet contains tartrazine dye, a risk for allergic patients

Climara

Climara delivers estradiol through a once-weekly patch, which may lower blood clot risk compared with oral estrogen by avoiding first-pass liver metabolism. It offers six dose strengths for fine-tuned titration but has no approved use for cancer treatment and can irritate the skin.

Pros

  • Once-weekly patch means far fewer doses than a daily pill

  • Skips first-pass liver metabolism, may lower clot risk

  • Six patch strengths allow precise, gradual dose adjustments

Cons

  • Not approved for palliative treatment of any cancer

  • Patch adhesive can cause skin redness or irritation

  • Patch is visible on the skin, which some patients dislike

Common Symptoms and Related Diseases You Can Explore

Explore a range of common symptoms the Doctronic Symptom Checker can help you understand.